


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.68%
-16.84%
VYGR
Voyager Therapeutics
$4.87
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market
VYGR Price Performance
$3.42 (+42.40%)
$4.36 (+11.70%)
$5.33 (-8.63%)
$3.65 (+33.42%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
VYGR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
VYGR Street Sentiment is extremely bullish and have positive views on the near-term outlook
VYGR has Medium risk level
Risk Indicators
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Jan 23, 2026
Initiate
Outperform
Wedbush
Nov 13, 2025
Reiterate
Buy
HC Wainwright & Co.
Nov 07, 2025
Reiterate
Overweight
KeyBanc
What is VYGR current stock price?
What are VYGR stock strengths?
What is VYGR Risk Level?
What is VYGR market cap and volume?
What is VYGR current Stock IQ?
Should I buy VYGR stock right now?
Is VYGR a Strong Buy right now?
What does a 'Strong Buy' rating mean for VYGR?
What does a 'Strong Sell' rating mean for VYGR?
What factors influence VYGR's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
VYGR
Voyager Therapeutics
Current Price
$4.87

VYGR Price Performance
$3.42 (+42.40%)
$4.36 (+11.70%)
$5.33 (-8.63%)
$3.65 (+33.42%)
VYGR Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
VYGR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
VYGR Street Sentiment is extremely bullish and have positive views on the near-term outlook
VYGR has Medium risk level
Risk Indicators
Average key support and resistance price levels
Overall Wall Street Rating
VYGR Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market
VYGR Latest Analysis
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG. BROOKLYN N.Y. March 11 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: VACHU VACH VACHW) (Voyager or the Company) today announced that holders of 25217315 of the Companys Class A ordinary shares (Class A shares) exercised their right to redeem their shares for a pro rata portion of the funds in the Companys trust account reflecting redemptions of appr
Wed Mar 11, 2026
Voyager Technologies Stock Surges After Q4 EPS Beat. Voyager Technologies Inc (NYSE:VOYG) shares are trading higher on Tuesday after the space and defense technology company posted fourth‑quarter results that featured a sizable adjusted EPS beat.Voyager Technologies stock is among today’.s top performers. Why are VOYG shares rallying?Voyager reported fourth‑quarter revenue of $46.65 million coming in just below the $48.22 million analysts expected. However the company delivered a much small
Tue Mar 10, 2026
Voyager Therapeutics (VYGR) Reports Q4 Loss Beats Revenue Estimates. Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 15.08% and 57.97% respectively for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Mon Mar 9, 2026
Voyager Therapeutics GAAP EPS of -$0.46 beats by $0.07 collaboration revenue of $15.34M beats by $4.85M.
Mon Mar 9, 2026
Voyager Technologies Stock Slides On Mixed Q4 Results. Voyager Technologies Inc (NYSE:VOYG) reported financial results for the fourth quarter after the market close on Monday. Here’.s a rundown of the report.Voyager Technologies shares are sliding. What’.s weighing on VOYG shares?Voyager Reports Mixed Results In Q4Voyager reported fourth-quarter revenue of $46.65 million missing analyst estimates of $48.22 million according to Benzinga Pro. The space and defense technology company repo
Mon Mar 9, 2026
Voyagers Starlab (VOYG) Customer Wins Signal Early Demand For Post-ISS Commercial Manufacturing in Low-Earth Orbit. Voyager Technologies Inc. (NYSE:VOYG) is one of the Best Space Stocks to Buy Now. On February 24 2026 LambdaVision secured reservations for commercial space in low-Earth orbit aboard the upcoming Starlab commercial space station a project led by Voyager Technologies through the Starlab Space LLC joint venture. The agreement gives LambdaVision payload slots and space [….]
Wed Mar 4, 2026
Voyager Therapeutics Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript.
Tue Mar 3, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
VYGR Stock trends
VYGR Stock performance
VYGR Stock analysis
VYGR investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.